3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasm Metastasis
3
Breast Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Rectal Neoplasms
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Mucositis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Mitomycin
15
Gemcitabine
13
dodecyl maltoside
5
BCG Vaccine
5
erdafitinib
4
apaziquone
4
ALT-803
4
Epirubicin
3
viscum album peptide
2
durvalumab
2
VB4-845
2
Imiquimod
2
Docetaxel
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
pirarubicin
1
pembrolizumab
1
linrodostat
1
hydroxycamptothecinum
1
enfortumab vedotin
1
catumaxomab
1
Water
1
Therapeutics
1
Therapeutic Uses
1
Standard of Care
1
Polysorbates
1
Photochemotherapy
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non-Muscle Invasive Bladder Neoplasms
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled